BioArctic

Declaration of Voting Results & Voting Rights Announcements • May 30, 2025

Press release

Number of shares and votes in BioArctic AB (publ) as of May 30, 2025

Stockholm, May 30, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 3,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 3,000 options of series 2019/2028.

As of May 30, 2025, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,531,485 shares, of which 74,131,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per share and the B share has one vote per share. The total number of votes in the company amounts to 218,131,449.

---

This information is information that BioArctic is obliged to make public pursuant to the Financial Instruments Trading Act. The information was released for public disclosure, through the agency of the contact persons below, on May 30, 2025, at 18:30 CET.

For further information, please contact:

Charlotte af Klercker, Senior Director Sustainability and Communications Phone: +46 73 515 09 70 E-mail: charlotte.afklercker@bioarctic.com

Anders Martin-Löf, CFO Phone: +46 70 683 79 77 E-mail: anders.martin-lof@bioarctic.com

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.